A growing body of evidence suggests mAbs that target a conserved epitope could be highly effective against SARS-CoV-2 and associated known mutations, according to the company. Prior research has shown that SARS-CoV-2 infection is mediated by the virus binding to the angiotensin-converting enzyme 2 (ACE2) entry receptor. Vir has developed two non-receptor binding motif (RBM)-targeting antibodies, VIR-7831 and VIR-7832, that target a conserved non-RBM site within the receptor binding domain (RBD).

Findings from the new research highlight the importance of three additional auxiliary receptors that enhance infection mediated by the ACE2 receptor. The study looked at the role of DC-SIGN and L-SIGN lectins in infection and further identified the SIGLEC1 lectin as a new participant in infection.

These auxiliary receptors also play an important role in modulating the neutralizing activity of different classes of spike-specific antibodies and may contribute to viral dissemination in the most severe COVID-19 cases, the company said. When tested in more physiologic conditions, with cells expressing low levels of ACE2 together with lectin receptors, non-RBM antibodies showed an enhanced ability to block viral infection, according to Vir.

Vir said the observation indicates the significant limitations of the use of cells overexpressing ACE2 for studies of mAbs and measuring serum neutralizing antibodies elicited by vaccination or infection.

GSK, Vir file EUA submission for COVID-19 mAb treatment
GlaxoSmithKline (GSK) and Vir Biotechnology filed an emergency use authorization (EUA) application with the U.S. Food and Drug Administration for VIR-7831...

Combination mAbs shown to be effective COVID-19 treatment
A phase II clinical trial collaboration among Eli Lilly, GlaxoSmithKline, and Vir Biotechnology has shown that a combination of two monoclonal antibodies...

Vir, GSK prepare to submit anti-COVID-19 mAb EUA
Vir Biotechnology and GlaxoSmithKline (GSK) are moving ahead with regulatory submission of their COVID-19 monoclonal antibody (mAb), VIR-7831, after a...

GSK, Vir partner on infectious diseases therapies
GlaskoSmithKline (GSK) and Vir Biotechnology have signed a deal to research and develop new therapies for influenza and other respiratory viruses.

SARS-CoV-2 mutation doesn't affect viral spread, but may limit therapies
As SARS-CoV-2 spreads around the globe, mutations of the virus are inevitable. An international team of researchers sought to define the effects of a...